Table 1.
Baseline characteristics of patient cases (N=178).
| Characteristics | Overall values, n (%) | |||
| Age (years), mean (SD) | 66 (13.9) | |||
| Sex | ||||
|
|
Female | 44 (24.7) | ||
|
|
Male | 134 (75.3) | ||
| Cancer types | ||||
|
|
Head and neck cancers | 109 (61.2) | ||
|
|
|
Oropharyngeal SCCa | 49 (27.5) | |
|
|
|
Oral cavity SCC | 22 (12.4) | |
|
|
|
Laryngeal SCC | 18 (10.1) | |
|
|
|
Hypopharyngeal SCC | 8 (4.5) | |
|
|
|
Other | 12 (6.7) | |
|
|
Thyroid cancers | 29 (16.3) | ||
|
|
|
Anaplastic thyroid carcinoma | 4 (2.2) | |
|
|
|
Differentiated thyroid carcinoma | 25 (14.0) | |
|
|
Skin cancers | 16 (9.0) | ||
|
|
Salivary gland cancers | 14 (7.9) | ||
|
|
|
Adenoid cystic carcinoma | 5 (2.8) | |
|
|
|
Nonadenoid cystic carcinoma | 9 (5.1) | |
|
|
Other cancers | 10 (5.6) | ||
| Cancer stage | ||||
|
|
|
Local/locally advanced | 121 (68.0) | |
|
|
|
Recurrent/metastatic | 57 (32.0) | |
| Biomarkers | ||||
|
|
Present | 66 (37.1) | ||
|
|
|
HPVb or p16c | 42 (23.6) | |
|
|
|
EBVd | 5 (2.8) | |
|
|
|
BRAFe mutation | 6 (3.4) | |
|
|
|
RETf mutation | 2 (1.1) | |
|
|
|
ARg | 2 (1.1) | |
|
|
|
HER2h | 3 (1.7) | |
|
|
|
Other | 6 (3.4) | |
|
|
None | 113 (63.5) | ||
| Treatment settings | ||||
|
|
|
Definitive | 93 (52.2) | |
|
|
|
Palliative | 51 (28.7) | |
|
|
|
Surveillance | 15 (8.4) | |
|
|
|
Adjuvant | 13 (7.3) | |
|
|
|
Diagnostic | 6 (3.4) | |
| Treatment modality | ||||
|
|
|
Combined modality therapy | 75 (42.1) | |
|
|
|
Primary systemic treatment | 37 (20.8) | |
|
|
|
Primary surgical treatment | 11 (6.2) | |
|
|
|
Primary radiation treatment | 8 (4.5) | |
|
|
|
Best supportive care | 5 (2.8) | |
|
|
|
Other | 24 (13.5) | |
|
|
|
Clinical trials | 18 (10.1) | |
aSCC: squamous cell carcinoma.
bHPV: human papillomavirus.
cp16: p16(INK4A) immunostain.
dEBV: Epstein-Barr virus.
eBRAF: V-Raf murine sarcoma viral oncogene homolog B.
fRET: Rearranged during transfection.
gAR: androgen receptor.
hHER2: human epidermal growth factor receptor 2.